The easiest way to get lost in the current 5-MeO-DMT drug-development story is to treat every company asset as if it were the same thing with a different label. That is wrong enough to matter.
GH Research’s GH001 and Beckley Psytech’s BPL-003 both sit on the 5-MeO-DMT / mebufotenin layer. But they are different company programs, with different formulations, routes, trial records, and evidence packages. The map is simple once you separate the compound name from the clinical asset.
The short map
GH001 is GH Research’s inhaled mebufotenin program. BPL-003 is Beckley Psytech’s intranasal 5-MeO-DMT benzoate program. They belong in the same conversation because they orbit the same compound family and the same broad question — can short-acting 5-MeO-DMT-like interventions become modern psychiatric medicines? They should not be collapsed into one generic “5-MeO drug.”
For readers, that distinction is not pedantry. It changes how you read trial results, regulatory claims, and company headlines. A result for GH001 is not automatically a result for BPL-003. A company release about BPL-003 does not rewrite the evidence base for GH001.
GH Research: GH001
GH001 is the cleaner evidence anchor right now because the treatment-resistant-depression story has a peer-reviewed spine. GH Research describes GH001 as its lead mebufotenin program, and the JAMA Psychiatry / PubMed anchor gives readers a source to use when they talk about the phase 2b signal rather than just the company narrative.
That is why the naming discipline from the mebufotenin explainer matters. Say GH001 when you mean the GH Research asset. Say mebufotenin or 5-MeO-DMT when you are talking about the compound-name layer. Keep the result attached to the exact program and study that produced it.
Beckley Psytech: BPL-003
BPL-003 is the Beckley Psytech program to keep next to GH001 on the map. The asset is usually framed as an intranasal 5-MeO-DMT benzoate formulation. Its treatment-resistant-depression story has a regulatory and company-readout spine, including FDA breakthrough-therapy language and positive topline results from Beckley / atai releases.
BPL-003 also has adjacent alcohol-use-disorder work. That matters because it shows Beckley is not only telling a TRD story. But it should stay in its lane: useful context for BPL-003’s program breadth, not a reason to turn this map into every atai or Beckley asset.
What transfers, and what does not
What transfers is the reader’s need for a better vocabulary. These programs all force the same basic habit: separate compound, formulation, route, sponsor, indication, and evidence tier.
What does not transfer cleanly is efficacy. GH001’s phase 2b signal belongs to GH001 and its study. BPL-003’s breakthrough designation, topline results, and registry records belong to BPL-003 and its studies. They can rhyme without being interchangeable.
The useful SCM read
The field is moving from psychedelic shorthand toward drug-development specifics. That is a good thing. The tradeoff is that every headline now needs a map. GH001 and BPL-003 are the two 5-MeO-DMT / mebufotenin programs to keep side by side, but the correct comparison is not “which 5-MeO-DMT headline sounds bigger?” It is: which formulation, which route, which indication, which evidence tier, and which source?
That is the whole discipline: same neighborhood, different assets. Keep the map clean and the evidence gets easier to read.
Source note
Primary anchors for this map are GH Research’s pipeline and clinical-trials pages, GH Research’s phase 2b publication release, the PubMed/JAMA GH001 paper anchor, ClinicalTrials.gov records for GH001 and BPL-003, and Beckley / atai releases for BPL-003 treatment-resistant-depression and alcohol-use-disorder readouts. Historical toad / Albert Most material is naming context only, not clinical evidence.